Volltext-Downloads (blau) und Frontdoor-Views (grau)

Cost-effectiveness study of antidiabetic drugs in type 2 diabetes mellitus patients from Mumbai, India

  • Background: Diabetes is fast gaining the status of a potential epidemic in India, with >62 million individuals currently diagnosed with the disease. India currently faces an uncertain future in relation to the potential burden that diabetes may impose on the country. An estimated US$ 2.2 billion would be needed to sufficiently treat all cases of type 2 diabetes mellitus (T2DM) in India. Many interventions can reduce the burden of this disease. However, health care resources are limited; thus, interventions for diabetes treatment should be prioritized. The present study assesses the cost-effectiveness of antidiabetic drugs in patients with T2DM from Mumbai, India. Methods: A prospective cross-sectional study was performed to assess the cost-effectiveness of antidiabetic drugs in patients with T2DM. Face-to-face interviews were conducted by using a validated questionnaire in a total of 152 (76 males, 76 females) patients with T2DM from F-North Ward, Mumbai, India. Cost-effectiveness was determined on the basis of cost of antidiabetic drug/s, efficacy, adverse drug reactions, safety of administration, frequency of administration, and bioavailability. Results: For treatment of T2DM in non-obese participants, Glimepiride+Pioglitazone costed least (`3.7) per unit of effectiveness followed by Glimepiride (`6.6), Gliclazide (`8.1), Repaglinide (`24.5), and Vildagliptin (`45.2). For treatment of T2DM in obese participants, Metformin cost least (` 6.7) per unit of effectiveness followed by Glimepiride + Metformin (`5.9) and Repaglinide (`24.5). Conclusions: In case of non-obese participants, cost effectiveness and prescribed treatments did not show a match, while for obese participants prescribed treatments were in line with cost effectiveness.

Download full text files

Export metadata

Additional Services

Share in Twitter Search Google Scholar

Statistics

frontdoor_oas
Metadaten
Author:Dnyanesh LimayeORCiDGND, Krishna Todi, Jay Shroff, Ashutosh Ramaswamy, Priyanka Kulkarni, Vaidehi Limaye, Gerhard FortwengelORCiDGND
URN:urn:nbn:de:bsz:960-opus4-19049
DOI:https://doi.org/10.25968/opus-1904
DOI original:https://doi.org/10.18203/2394-6040.ijcmph20173653
Parent Title (English):International Journal of Community Medicine and Public Health
Document Type:Article
Language:English
Year of Completion:2017
Publishing Institution:Hochschule Hannover
Release Date:2021/03/31
Tag:Antidiabetic; Cost-effectiveness; Diabetes mellitus; India
GND Keyword:Diabetes mellitus Typ 2; Antidiabetikum; Indien; Effizienz
Volume:4
Issue:9
First Page:3180
Last Page:3185
Institutes:Fakult├Ąt III - Medien, Information und Design
DDC classes:610 Medizin, Gesundheit
Licence (German):License LogoCreative Commons - CC BY-NC - Namensnennung - Nicht kommerziell 4.0 International